Significant hair regrowth was achieved using 1mg finasteride and 5% topical minoxidil over 14 months, with only initial shedding and mild scalp irritation as side effects. Consistency and early treatment are recommended for optimal results.
Low-Level Laser Therapy (LLLT) is seen as a safe and effective method for maintaining hair and promoting regrowth in androgenetic alopecia (AGA) and male pattern baldness (MPB), with devices like the HairMax LaserComb® and iRestore helmet being popular. Some users and professionals are skeptical about its long-term effectiveness and cost.
A user's 14-month journey with finasteride, microneedling, and Nizoral to treat hair loss. They experienced some side effects such as ball ache, needing to pee constantly, and less semen, but the results were generally positive.
The user experienced worsening hair loss despite using finasteride, minoxidil, and microneedling. Suggestions included reducing microneedling frequency, switching to oral minoxidil, adding tretinoin, and considering dutasteride.
The user reports progress in hair regrowth using topical finasteride/minoxidil, microneedling, topical dutasteride, latanoprost, and MSM supplements. They express frustration over the lack of interaction on progress posts compared to trivial topics.
A 14-year-old experiencing hair loss is seeking advice after using minoxidil and derma stamping without noticeable results. They are advised to continue using minoxidil, as it may take time to show effects.
Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.
Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. HMI 115 shows anecdotal success in Phase I trial, users seek group buy for research chemical.
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
This user "ateaninja" has been using finasteride and minoxidil for 14 months along with weekly micro-needling for the last 5 months to treat hair loss. They also have a trusted barber to make their existing hair look fuller.
The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.
A user shared 14-month progress pictures using topical finasteride and minoxidil for hair loss. Others commented on the impressive results and asked about age, improvement timeline, and how to obtain finasteride.
The user experienced high liver enzyme levels, possibly due to topical finasteride or supplements, and decided to stop using finasteride while continuing minoxidil. After stopping finasteride and supplements, liver levels returned to normal, suggesting finasteride or supplements might have been the cause.
A user ordered RU58841 from a Chinese supplier, found it to be less than 99% pure, and plans to try a different seller next time. Concerns were raised about impurities, but the user believes they are likely inactive fillers rather than harmful substances.
An 18-year-old experienced severe side effects, including heart palpitations and high blood pressure, after using RU58841 once, leading to a referral to cardiology for suspected left ventricular hypertrophy. The user regrets using RU58841 and seeks advice on recovery, while others suggest preexisting conditions or genetic predispositions may be factors.
RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.
The user has been on a hair loss treatment for 14 months using dutasteride and oral minoxidil without seeing regrowth and is considering adding more drugs due to the psychological impact of hair loss. However, replies suggest the user may not actually be experiencing noticeable hair loss.
A user shared a 14-month hair loss treatment update using dutasteride, minoxidil foam, a 1.5mm derma roller, and Nizoral, with noticeable hair regrowth and no side effects. The discussion highlights the effectiveness of microneedling in combination with topical treatments, with many users agreeing it significantly enhances results.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115 release timeline is uncertain, with possible grey market availability in 2024-2025.
A user ingested RU58841 orally and experienced severe heart and breathing issues, requiring emergency medical assistance. They concluded that MV supplements is a legitimate supplier but warned of the serious side effects.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.
The user is seeking alternative hair loss treatments due to side effects from finasteride and minoxidil. They are inquiring about the availability of gt20029 from u-lab.
A user shared their 14-year experience with hair loss treatments, primarily using finasteride, minoxidil, and Nizoral. They highlighted the effectiveness of finasteride despite some side effects and emphasized the importance of early prevention and the potential for negative selection bias in online reviews.
Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.
The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.
The user shared their hair regrowth journey using treatments like dutasteride, minoxidil, microneedling, tretinoin, Nizoral, silica, biotin, and hormone replacement therapy (HRT) with cyproterone and estradiol. They reported substantial hairline improvement and some crown thinning, with hopes for further progress.
The conversation discusses the sale of a premixed KY19382 solution for research purposes, highlighting previous unsuccessful group buys and the formulation process. Prices and purchasing options for KY19382 solutions and powder are provided.